1. Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome

3. Introduction

4. Treatment Goals in Lower-Risk* MDS

5. Case 1: 72-Year-Old Woman

6. Patient Risk Stratification

7. Considerations for First-Line ESA

8. MDS-003 Study

9. MDS-004 Study

10. Long-Term Results With Lenalidomide

11. Lenalidomide in Non-del(5q)

12. Lenalidomide in Non-del(5q): Raza et al

13. Lenalidomide in Non-del(5q): MDS-005

14. Case 2: 66-Year-Old Man

15. Prognostic Value of Mutations

16. Effect of Mutations on Survival

17. SF3B1 and Ring Sideroblasts

18. Considerations for Ring Sideroblasts

19. Experimental Therapies Targeting Activin Receptor II Binding Targets

20. SF3B1 Modulators in Development

21. Case 3: 78-Year-Old Man

22. Diagnosis of MDS

23. CHIP Analyses

24. Hypomethylating Agents

25. Immunosuppressive Therapy

26. Thrombopoietin Receptor Agonists

27. Concluding Remarks

28. Abbreviations

29. Abbreviations (cont)